Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target

April 29, 2019

Calixar has given Regeneron exclusive rights to its technology and expertise to conduct research and discovery of antibodies against an undisclosed target in various therapeutic fields.

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.